Early prediction of treatment outcome for lenvatinib using ^18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study

Background Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas.

We aimed to determine whether ^18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict treatment outcomes.

Results This was a prospective, nonrandomised, multicentre study.

Patients with pathologically confirmed differentiated thyroid carcinoma (DTC) and lesions refractory to radioiodine treatment were eligible for inclusion.

Patients were treated with 24 mg lenvatinib as the initial dose and underwent PET/CT examination 1 week after treatment initiation.

Contrast-enhanced CT was scheduled at least 4 weeks later as the gold standard for evaluation.

The primary endpoint was to evaluate the discrimination power of maximum standardised uptake value (SUVmax) obtained by PET/CT compared to that obtained by contrast-enhanced CT.

Evaluation was performed using the area under the receiver operating characteristic (ROC-AUC) curve.

Twenty-one patients were included in this analysis.

Receiver operating characteristic (ROC) curve analysis yielded an AUC of 0.714 for SUVmax after 1 week of lenvatinib treatment.

The best cut-off value for the treatment response for SUVmax was 15.211.

The sensitivity and specificity of this cut-off value were 0.583 and 0.857, respectively.

The median progression-free survival was 26.3 months in patients with an under-cut-off value and 19.7 months in patients with an over-cut-off value ( P  = 0.078).

Conclusions The therapeutic effects of lenvatinib were detected earlier than those of CT because of decreased FDG uptake on PET/CT.

PET/CT examination 1 week after the initiation of lenvatinib treatment may predict treatment outcomes in patients with DTC.

Trial registration : This trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (number UMIN000022592) on 6 June, 2016.